Influx Healthtech Guides 25-30% Topline Growth Amid Capacity Expansion and Segmental Strength

Influx Healthtech Guides 25-30% Topline Growth Amid Capacity Expansion and Segmental Strength​

India, July 10, 2026: Influx Healthtech Limited, an innovation-driven CDMO, released a business update for the quarter ended June 30, 2026 (Q1FY27), highlighting strong operational improvements and significant capacity expansion plans as it aims to drive stakeholder value.

The company reported healthy growth across all business verticals, driven by a favorable business mix and improved operating efficiencies, which led to stronger profitability and margin expansion. Enhanced working capital efficiency was also noted through better receivables and inventory management, supported by strong client retention reflecting long-term relationships and consistent product quality.

Strategic Investment and Capacity Boost​

A key operational development involves a strategic reallocation of ₹ 10 Crs towards expanding the nutraceutical CDMO facility. The existing facility, approximately 35,000 sq. ft., is set to be expanded up to 75,000 sq. ft., with the new capacity expected to become operational by August 2026. Upon full commissioning of this enhanced facility and increased utilization at existing sites, Influx Healthtech anticipates a 2.5x capacity uplift.

Segmental Achievements in Q1FY27​

The company showcased robust performance across its diverse segments:

• Nutraceuticals: A new tablet granulation line was commissioned, capable of processing approximately 480 kg/day and supporting the production of about 24,000 bottles per day.
• Beverage Manufacturing: Infrastructure expansion includes high-capacity lines for canning, carbonated beverages, and Tetra Pak, boasting a capacity of 10,000 bottles per hour.
• Pet Nutrition: Pet nutrition capacity is being expanded from 16 to 18 tonnes/month toward 25 tonnes/month in response to growing customer demand. To support long-term growth, the company has ordered a high-capacity pet food extrusion line, which will increase processing capability from 100 to 150 kg/hour to 1,000 kg/hour.
• Cosmetics: Investments were made in innovative cosmetics machinery sourced from China to support differentiated cream formulations with enhanced visual appeal.

In addition to manufacturing capacity increases, Influx Healthtech expanded its diversified product portfolio across more than 3,400 SKUs, enabling customized solutions across healthcare and wellness categories. The company has also developed innovative, palatable pet chew formulations to enhance pet healthcare offerings.

Outlook and Financial Guidance for FY27​

Management expressed confidence in sustaining execution momentum into the fiscal year 2027 (FY27).

The guidance set for FY27 includes:

• Topline Growth: Expected at approximately 25–30%.
• EBITDA Margins: Guided at roughly 20–22%.

The strategy for FY27 focuses on scaling existing customer relationships and expanding into premium product categories. The company plans to strengthen its presence through Olahey Wellness Pvt. Ltd. while extending product offerings across Clinical & Functional Nutrition, Cosmetic Innovation, and Pet Nutrition.

Furthermore, Influx Healthtech reported progress in international expansion, noting successful regulatory approval in Tanzania, which supports continued export activities across Nigeria, Kenya, and other global markets.

INFLUX Stock Price Movement​

Influx Healthtech Limited's shares slipped by 0.65% today, settling at ₹289 in post-market trading. The stock traded a total of 21,600 shares, closing lower after hitting an intraday high of ₹299.